SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Towards a sustainable system of drug development
16 references·0 citing·39 second hop
Towards a sustainable system of drug development (2014)Towards a sustainable system of drug deve…priority Medicines for Europe and the World: 2013 update (2013)priority Medicines for Europe…Models for open innovation in the pharmaceutical industry (2013)Models for open innovation in…Challenges and opportunities of drug repositioning (2013)Challenges and opportunities …The productivity crisis in pharmaceutical R&D (2011)The productivity crisis in ph…The cost of drug development: A systematic review (2011)The cost of drug development:…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Deconstructing the Drug Development Process: The New Face of Innovation (2010)Deconstructing the Drug Devel…Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Rebuilding the R&D engine in big pharma. (2008)Rebuilding the R&D engine in …Drug discovery: new models for industry–academic partnerships (2008)Drug discovery: new models fo…Against Intellectual Monopoly (2008)Against Intellectual MonopolyDrug discovery in jeopardy (2006)Drug discovery in jeopardyThe Economics of Follow-on Drug Research and Development (2004)The Economics of Follow-on Dr…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry 1977–1986 (1991)A longitudinal study of the c…Increasing Returns and Long-Run Growth (1986)On the mechanics of economic development (1988)The Theory of Economic Development (2003)Reconsidering the Bayh-Dole Act and the Current University Invention Ownership Model (2009)Competition and Innovation: The Inverted-U Relationship Revisited (2013)The Effects of Government-Sponsored Venture Capital: International Evidence (2014)The price of innovation: new estimates of drug development costs (2003)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Clinical development success rates for investigational drugs (2014)Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients (2020)Drug repurposing: a systematic review on root causes, barriers and facilitators (2022)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Key cost drivers of pharmaceutical clinical trials in the United States (2016)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The black swan: the impact of the highly improbable (2007)THE WORLD MEDICINES SITUATION 2011 (2011)Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)Risks in new drug development: Approval success rates for investigational drugs (2001)The cost of biopharmaceutical R&D: is biotech different? (2007)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Exploring different approaches to improve the success of drug discovery and development projects: a review (2020)The past, present and future of open innovation (2020)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Changing R&D models in research-based pharmaceutical companies (2016)A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)Prospects for productivity (2004)Drug discovery in academia: the third way? (2010)US academic drug discovery (2011)Racing to define pharmaceutical R&D external innovation models (2014)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)The impact of mergers on pharmaceutical R&D (2011)Big Pharma, little science? (2012)Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry (2018)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,167 cited
  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2008Against Intellectual Monopoly921 cited
  • 2011The productivity crisis in pharmaceutical R&D918 cited
  • 2011The cost of drug development: A systematic review510 cited
  • 2010Deconstructing the Drug Development Process: The New Face of Innovation422 cited
  • 2013Challenges and opportunities of drug repositioning375 cited
  • 2008Rebuilding the R&D engine in big pharma.230 cited
  • 2006Drug discovery in jeopardy209 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 2004The Economics of Follow-on Drug Research and Development189 cited
  • 1991A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry 1977–1986164 cited
  • 2013Models for open innovation in the pharmaceutical industry148 cited
  • 2008Drug discovery: new models for industry–academic partnerships140 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2013priority Medicines for Europe and the World: 2013 update140 cited
  • Cited by

    No citing works inside the corpus for this window.